Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer

British Journal of Cancer

Volumn 99, Issue 8, 2008, Pages 1232-1238

  Hisashige, A ^a   Yoshida, S ^b   Kodaira, S ^c  

^a Institute of Healthcare Technology Assessment   (Japan)

^b AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c Nerima General Hospital   (Japan)

Author keywords

Adjuvant therapy; Economic evaluation; Rectal cancer; Uracil tegafur

Indexed keywords

UFT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECTUM CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RECTAL NEOPLASMS; TEGAFUR; URACIL;

EID: 53849100997     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604666     Document Type: Article

References (52)

1. Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J (2007) Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 109: 1082-1089
2. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr 19: 716-723
3. Akasu T, Moriya Y (1997) Abdominopelvic lymphadenectomy with autonomic nerve preservation for carcinoma of the rectum: Japanese experience. In Surgery for Gastrointestinal cancer: a Multi-Disciplinary Approach, Wanebo HJ (ed), pp 667-680. Lippincott-Raven: Philadelphia
4. Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S (2006) Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 36: 237-244
5. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. NEJM 350: 2343-2351
6. Bajetta E, Bartolomeo MD, Buzzoni R, Mariani L, Zilembo N, Ferrario E, Vullo SL, Aitini E, Isa L, Barone C, Jacobelli S, Recaldin E, Pinotti G, Iop A on behalf of the ITMO group (2007) Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer 96: 439-444
7. Bennouna J, Perrier H, Paillot B, Priou F, Jacob JH, Hebbar M, Bordenave S, Seitz JF, Cvitkovic F, Dorval E, Malek K, Tonelli D, Douillard JY (2006) A phase II study of oral uracil/ftorafur (UFTs) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer 94: 69-73
8. Beretta GD, Milesi L, Pessi MA, Mosconi S, Labianca R (2004) Adjuvant treatment of colorectal cancer. Surg Oncol 13: 63-73
9. Bernold DM, Sinicrope FA (2006) Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 4: 808-821
10. Boag JW (1949) Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J Roy Stat Soc B 11: 15-53
11. Bos JM, Postma MJ, Annemans L (2005) Discounting health effects in pharmacoeconomics evaluations: current Controversies. Pharmaco-economics 23: 639-649
12. Briggs AH (2004) Statistical approaches to handling uncertainty in health economic evaluation. Eur J Gastroenterol Hepatol 16: 551-561
13. Brouwer WB, Niessen LW, Postma MJ, Rutten FF (2005) Need for differential discounting of costs and health effects in cost-effectiveness analyses. BMJ 331: 446-448
14. Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M (2000) Preoperative radiotherapy for resectable rectal cancer. JAMA 284: 1008-1015
15. Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ (2004) When does quality-adjusted life-years matter in cost-effectiveness analysis? Health Econ 13: 429-436
16. Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomized trials. Lancet 358: 1291-1304
17. Committee of Cancer Statistics (2005) Cancer Statistics 2005. Tokyo (in Japanese): Foundation of Promotion of Cancer Research
18. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd ed Oxford Univ Press: NY
19. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ (2000) Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18: 3302-3317
20. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Caplan R, Jones J, Lerner H (1988) Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer. Results from NSABP protocol R-01. J Natl Cancer Inst 80: 21-29
21. Glick HA, Briggs AH, Polsky D (2001) Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Rev Pharmacoeconomics Outcome Res 1: 89-100
22. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-Effectiveness in Health and Medicine. Oxford Univ Press: NY
23. Gross AJ, Clark VA (1975) Survival distributions: Reliability Applications in the Biomedical Sciences. John Wiley & Sons: NY
24. Institute of Social Insurance (2005) Interpretation for Table of Points of Medical Practice. Institute of Social Insurance: Tokyo (in Japanese)
25. Jansman FGA, Postma MJ, Brouwers JRBJ (2007) Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 25: 537-562
26. Japanese Society for Cancer of the Colon and Rectum (2005) Treatment Guidelines for Colorectal Cancer, 2005 version, Kanehara: Tokyo (in Japanese)
27. Jiho (2005) Encyclopedia of Drugs Listed for Insurance. Jiho Inc.: Tokyo (in Japanese)
28. Jonsson B (2004) Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 22(Suppl 4): 5-10
29. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ, Dutch Colorectal Cancer Group (2001) Preoperative radiotherapy combined with total mesorectal excision for respectable rectal cancer. NEJM 345: 638-646
30. Kato T, Ohashi Y, Nakazato H, Koike A, Saji S, Suzuki H, Takagi H, Nimura Y, Hasumi A, Baba S, Manabe T, Maruta M, Miura K, Yamaguchi A (2002) Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch Surg 386: 575-581
31. Kodaira S, Kikuchi K, Yasutomi M, Takahashi T, Hojo K, Kato T, Tominaga T, Kunii Y (1998) Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results form the Cooperative Project No.7 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer. Int J Clin Oncol 3: 357-364
32. Lee ET, Go OT (1997) Survival analysis in public health research. Ann Rev Pub Health 18: 105-134
33. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24: 2059-2064
34. Lin DY, Feuer EJ, Etzioni R, Wax Y (1997) Estimating medical costs from incomplete follow-up data. Biometrics 53: 419-434
35. Maetani S, Nakajima T, Nishikawa T (2004) Parametric mean survival time analysis in gastric cancer patients. Med Decis Making 24: 131-141
36. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer (2004) Efficacy of oral adjuvant therapy after resection of colorectal cancer, 5-year results from three randomized trials. J Clin Oncol 22: 484-492
37. Ministry of Health, Labor and Welfare (2006) Outline of Vital Statistics. MHLW, (in Japanese)
38. Monga DK, O'Connell MJ (2006) Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. Ann Surg Oncol 13: 1021-1034
39. Mori T, Takahashi K, Yasumo M (1998) Radical resection with autonomic nerve preservation and lymph node dissection techniques in lower rectal cancer surgery and its results: the impact of lateral lymph node dissection. Langenbecks Arch Surg 383: 409-415
40. National Institute of Clinical Excellence (2004) Guide to the Methods of Technology Appraisal. NICE: London
41. Ness RM, Holmes AM, Klein R, Dittus R (1999) Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 94: 1650-1657
42. Norum J, Vonen B, Olsen JA, Revhaug A (1997) Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma, a cost-effectiveness analysis. Ann Oncol 8: 65-70
43. OECD (2007) GDP PPPs and Delivered Indices for all OECD Countries, OECD Main Economic Indicators. OECD
44. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA (2005) Late side effect of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients, a Dutch Colorectal Cancer Group Study. J Clin Oncol 23: 6199-6206
45. Ragnhammar P, Hafström L, Nygren P, Glimelius B, SBU-group. Swedish Council of Technology Assessment in Health Care (2001) A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncologica 40: 282-308
46. Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y (1999) Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 29: 78-86
47. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. NEJM 351: 1731-1740
48. Takiuchi H (2006) Adjuvant therapy in rectal cancer: what is the truth? Jpn J Clin Oncol 36: 191-192
49. Trueman P, Drummond M, Hutton J (2001) Developing guidance for budget impact analysis. Pharmacoeconomics 19: 609-621
50. Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. NEJM 352: 2696-2704
51. van den Hout WB, van den Brink M, Stiggelbout AM, van de Velde CJ, Kievit J (2002) Cost-effectiveness analysis of colorectal cancer treatments. Eur J Cancer 38: 953-963
52. Willan AR, Briggs AH (2006) Statistical Analysis of Cost-Effectiveness Data. John Wiley & Sons: Chichester